Annual Heart in Diabetes conference offers all-virtual sessions on cardiometabolic health
Organizers behind this year’s Heart in Diabetes conference are preparing to launch a free, all-virtual platform of sessions spanning all aspects of cardiometabolic health, along with a new emphasis on the impact of the COVID-19 pandemic.
Leading experts from a range of specialties will once again come together — this time online — to address the relationship between type 2 diabetes, cardiovascular and renal disease along with the latest research demonstrating their interconnectedness, according conference co-chair Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE. The now 4-day CME conference, described as where the heart, kidney and diabetes meet in clinical practice, will take place Friday through Monday. The agenda includes sessions that span the subspecialties from cardiology, lipidology and endocrinology to nephrology, hepatology and primary care, with an emphasis on the latest guidelines and data from important CV outcomes trials.
“In terms of the virtual program, attendees are not going to lose anything,” Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, also medical director and principal investigator of the Metabolic Institute of America in Tarzana, California, and an Endocrine Today Editorial Board Member, told Healio. “We have speakers from all over the world. The original program, taking place in New York City Friday through Sunday noon, was a very condensed program. Now we have the ability to spread the program over 4 days. We also had the ability to add more discussion time and more time for questions from our attendees. That will enhance the experience attendees will get from the program.”
Attendees can earn up to 28 free CME credits, a first for the conference, with all sessions available for 90 days after the program concludes, Handelsman said.
“We have about tripled the attendance for this year’s meeting,” Handelsman said.
Conference highlights include the following:
- On Friday at 3:45 p.m., Heart in Diabetes with Circulation will feature presentations on the “diabetes paradox” in aortic aneurysm with Joshua Beckman, MD, heart failure stratification and efficacy of SGLT2 inhibitors with Benjamin M. Scirica, MD, and sugar-sweetened beverages and CV risk with Alice H. Lichtenstein, DSc.
- Deepak L. Bhatt, MD, will chair a Saturday session on advances in antithrombotic therapy in diabetes (11:20 a.m. to 12:40 p.m.), including an analysis of the COMPASS trial.
- Two debates during the meeting will focus on whether treatment with PCSK9 inhibitors should be reserved for individuals with an LDL cholesterol of at least 100 mg/dL (featuring Jennifer G. Robinson, MD, and Steven E. Nissan, MD and on whether early combination or sequential therapy has a greater impact on diabetes and CV risk (featuring David M. Nathan, MD, and Stefano Del Prato, MD).
- On Sunday at 1:30pm, Heart In Diabetes with Journal of the American College of Cardiology will feature presentations on atrial fibrillation and diabetes with Allen Wang, MD, SGLT2 inhibition and cardiorenal protection with Julie A. Lovshin, MD, PhD, and individualizing revascularization strategy for diabetic patients with multivessel CAD with David J. Cohen, MD. At 3:10 p.m., sessions begin on the state of heart failure research with Peter Reaven, MD, blood pressure variability, HF and diabetes with Mark Kearney, MD, and the latest on the DAPA-HF trial with John McMurray, MD.
- Monday sessions will highlight the latest in renal research, with sessions on GLP-1 receptor agonists in atherosclerotic CVD and the kidney (chaired by Richard E. Pratley, MD and Matthew R. Weir, MD) and the kidney and the heart (chaired by Christian W. Mende, MD, and Robert J. Chilton, DO).
- The year’s “Luminary in Cardiometabolic Medicine” award will be presented to Eugene Braunwald, MD, who will also present the keynote talk on SGLT2 inhibitors and the birth of two paradigm shifts in clinical care.
The conference will also include a special emphasis on COVID-19 and cardiometabolic outcomes, including the DARE-19 trial, a global phase 3 trial that is now underway to assess the potential of the SGLT2 inhibitor dapagliflozin as a treatment to reduce COVID-19 progression, complications and death among adults with cardiovascular, metabolic or renal risk factors, Handelsman said.
“We are fortunate that our faculty is very much involved in different ongoing studies related to COVID-19, particularly among people who have obesity or diabetes,” Handelsman said. “We are looking at the latest research going on in this area as well as something very important and a growing area of concern — the impact on CV care post-pandemic. Many people are not doing the preventive work.”
The Cardiology Today and Endocrine Today staffs will provide coverage from Heart in Diabetes 2020, including reports on the sessions, debates and much more. For more information on the Heart in Diabetes conference and registration, visit www.heartindiabetes.com.